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Abstract
Background: Renal cell carcinoma (RCC) represents one of the most immunoresponsive cancers. Antigen-specific
vaccination with dendritic cells (DCs) in patients with metastatic RCC has been shown to induce cytotoxic T-cell
responses associated with objective clinical responses. Thus, clinical trials utilizing DCs for immunotherapy of
advanced RCCs appear to be promising; however, detailed analyses concerning the distribution and function of DC
subsets in RCCs are lacking.
Methods: We characterized the distribution of the different immature and mature myeloid DC subsets in RCC
tumour tissue and the corresponding normal kidney tissues. In further analyses, the expression of various
chemokines and chemokine receptors controlling the migration of DC subsets was investigated.
Results: The highest numbers of immature CD1a+ DCs were found within RCC tumour tissue. In contrast, the
accumulation of mature CD83+/DC-LAMP+ DCs were restricted to the invasive margin of the RCCs. The mature
DCs formed clusters with proliferating T-cells. Furthermore, a close association was observed between MIP-3a-
producing tumour cells and immature CCR6+ DC recruitment to the tumour bed. Conversely, MIP-3b and SLC
expression was only detected at the tumour border, where CCR7-expressing T-cells and mature DCs formed
clusters.
Conclusion: Increased numbers of immature DCs were observed within the tumour tissue of RCCs, whereas
mature DCs were found in increased numbers at the tumour margin. Our results strongly implicate that the
distribution of DC subsets is controlled by local lymphoid chemokine expression. Thus, increased expression of
MIP-3a favours recruitment of immature DCs to the tumour bed, whereas de novo local expression of SLC and
MIP-3b induces accumulation of mature DCs at the tumour margin forming clusters with proliferating T-cells
reflecting a local anti-tumour immune response.
Background
Dendritic cells (DCs) are the most potent antigen-present-
ing cells (APCs), and play a central role in the processing
and presentation of antigens to T cells during an immune
response [1]. DC progenitors in the bone marrow give rise
to circulating precursors that home to the tissue where
they reside as immature cells with high phagocytic capa-
city. Upon tissue damage or exposure to antigens, DCs
capture antigens and subsequently migrate to the lym-
phoid organs, where they select the rare antigen-specific
T cells and initiate a cellular immune response [1,2]. It has
been shown that during migration and within secondary
or tertiary lymphoid organs, DCs undergo functional
maturation from antigen collection and processing to very
potent APCs [1,3,4]. Immature DCs capture antigens, but
weakly stimulate T lymphocytes. In the presence of parti-
cular signals, such as lipopolysaccharide (LPS) or various
cytokines, immature DCs mature into potent T stimula-
tory cells, a process that is associated with up-regulation
of co-stimulatory molecules (CD80, CD86, CD40, CD83,
and DC-LAMP), as well as changes in chemokine recep-
tors expressed on their surface [1-6]. Immature CD1a+
DCs are CC-chemokine-receptor (CCR) 6-positive and
respond to MIP-3a [7]. In contrast, mature DCs are
attracted by the chemokine, MIP-3ß, or secondary
lymphoid chemokines (SLCs) following de novo expression
of CCR7 [6,8,9]. A critical characteristic of fully mature
DCs is the production of pro-inflammatory cytokines,
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particularly IL-12, which plays a critical role in the induc-
tion of efficient T-helper cell 1 immunity [10], as observed
for an efficient anti-tumour T cell response [1,6].
The involvement of DCs in tumour immunity has
clinical importance. The infiltration of DCs into some
primary tumour types has been found to be associated
with significantly improved patient survival and a
reduced incidence of recurrent disease [11,12]. It is
known that tumours avoid surveillance by the immune
system through various mechanisms, including the inhi-
bition of the recruitment of DCs at the tumour site, as
well as impairment of function of DCs by local produc-
tion of immunosuppressive cytokines [13]. However, the
precise knowledge of the tumour environment, which
varies between different tumour types, might be impor-
tant for the design of optimal immunotherapeutic strate-
gies against cancer [14-16].
Promising results have been previously reported using
DC-based vaccination against immunogenic tumours,
such as melanoma or renal cell carcinoma (RCC) [17,18].
A subset of patients with metastatic RCC develops signif-
icant immune and clinical responses after immunother-
apy with DC vaccination [1]. In this context mature DCs
are thought to play a key role, since they are known to
represent the most effective antigen presenting cells for
induction of a potent T cell response. In order to give an
answer to the question why some patients respond to
DC-vaccine based therapies and others not, a detailed
knowledge about the cellular T cell immune response in
RCC with special regard to antigen-presenting DCs is
required. However, detailed studies concerning the type
and distribution of DC subsets in RCC are still lacking.
More recently, novel markers have emerged allowing
the identification of a broader spectrum of DC subpopu-
lations with respect to their function on formalin-fixed
and paraffin-embedded tissue. Thus, we characterized
the phenotype, distribution, and maturation of the dif-
ferent DC subsets in RCCs. In addition, we analyzed the
local expression of chemokines that are known to play a
key role for the recruitment of DC subsets.
Methods
Tissue samples
Tumours and corresponding tumour-free tissue of
nephrectomy specimens from 24 patients with RCCs
were included in this study. All tumours were freshly
obtained from the Urologic Department’s operating
room. The patient ages ranged from 36-75 years (med-
ian age, 60 years). None of the patients investigated in
this study were treated before surgery. The formalin-
fixed and paraffin-embedded specimens were cut into
5-μm-thick sections and placed on poly-L-lysine-treated
glass slides. Representative sections were stained with
routine hematoxylin and eosin (H&E) and evaluated.
The histologic types of cancer were as follows: clear cell
(n = 17); papillary (n = 4); chromophobe (n = 1); and
sarcomatoid renal cell carcinoma (n = 2). This study
was approved by the Ethics Committee of Georg-
August-University Göttingen, and the Helsinki Declara-
tion regarding the use of human tissue was followed.
Informed consent was obtained from the patients for
the use of their tissue samples.
Immunohistochemistry
The antibodies used in the study and the optimal work-
ing dilutions are listed in Table 1. The sections were
immunostained applying the biotin-streptavidin-peroxi-
dase method (Multi-Link, DCS, Hamburg, Germany).
Immunostaining for chemokines (MIP-3a, MIP-3b, and
SLC) required application of the tyramide signal amplifi-
cation system method (NEN, Boston, MA, USA). In
control reactions, isotype- and species-specific matched
control antibodies were applied.
For double immunofluorescence staining, the slides
were stained for 1 hour with unconjugated primary anti-
body, followed by incubation with indocarbocyanine
2 (Cy2)-conjugated goat anti-mouse or goat anti-rabbit F
(ab)-fragments (both from Dianova, Hamburg, Germany)
at a saturating concentration for 60 minutes. For the first
Table 1 Antibodies used for immunohistochemistry and
immunofluorescence (Ms - mouse, Rb - rabbit antibody)
Antibody Dilution Species Vendor
CD1a 1:50 Ms LabVision, Fremont, CA, USA
CD3 1:50 Ms Novocastra, Newcastle, UK
CD4 1:50 Ms DAKO, Hamburg, Germany
CD11c 1:50 Ms DAKO
CD40 1:50 Ms Acris, Hiddenhausen, Germany
CD68 1:50 Ms DAKO
CD79a 1:50 Ms DAKO




Langerin 1:50 Ms Acris
RelB 1:200 Rb SantaCruz
CCR6 1:20 Ms R&D Systems
CCR7 1:20 Ms R&D Systems
MIP-3a 1:20 Goat R&D Systems
MIP-3b 1:20 Goat R&D Systems
SLC 1:50 goat R&D Systems
Vimentin 1:100 Ms DAKO
Fascin 1:100 Ms DAKO
D2-40 No Ms DCS-Diagnostics, Hamburg,
Germany
Ki-67 1:50 Ms DAKO
Middel et al. BMC Cancer 2010, 10:578
http://www.biomedcentral.com/1471-2407/10/578
Page 2 of 12
step in immunofluorescence staining for MIP-3a, MIP-
3b, and SLC, we adopted the TSA-Kit (NEN) using
FITC-conjugated tyramide for fluorescence amplification.
Sections were washed and incubated with the second
antibody for 60 minutes at room temperature, followed
by incubation with indocarbocyanine 3 (Cy3)-conjugated
goat anti-mouse or goat anti-rabbit F(ab)-fragments
(both from Dianova) for 60 min at room temperature.
Confocal fluorescence images were obtained on a
Leica TCS (Leica Microsystems, Heidelberg, Germany)
confocal system mounted on an Olympus BX50 WI
microscope (Tokyo, Japan). Possible cross-talk between
FITC or Cy2 and Cy3, which could give rise to false-
positive co-localization of different signals, was avoided
by careful selection of the imaging conditions.
RT-PCR analysis
Sequences of primers used in the study are listed in
Table 2. Primers and probes (Operon-Qiagen, Hilden,
Germany) were designed using the Primer-3 online pri-
mer design program http://www-genome.wi.mit.edu.
Optimal conditions for all primers were established by
amplifying cDNA samples from human tonsil or lymph
node.
Total cellular mRNA was extracted with the RNeasy
Mini Kit (Operon-Qiagen). RNA integrity and quantity
was assessed using the Agilent Bio-analyzer 2100 (Agilent
Technologies, Waldbronn, Germany). Reverse transcrip-
tion with random hexamer primers was performed with
the Omniscript RT Kit (Qiagen). Quantification of MIP-
3a, MIP-3b, SLC, and ß-actin mRNA expression was
performed on an iCycler iQ real-time detection system
(Bio-Rad, Hercules, CA, USA) using the HotStar
TaqDNA polymerase kit (Qiagen). Expression of MIP-
3a, MIP-3b, and SLC was normalized to ß-actin expres-
sion to compensate for different sample capacities.
Results derived from the PCR standard curve are given in
attomoles per μg of total cellular RNA. cDNA from a
human lymph node was used as a positive control tem-
plate for each primer pair. Negative controls with water
instead of cDNA were always included.
Tumour cell lines
The RCC cell lines (A498, Caki-1, and Caki-2) were
purchased from the Deutsche Sammlung von Mikroor-
ganismen und Zellkulturen (DSZM, Braunschweig,
Germany). All 3 cell lines were cultivated at 37°C in 5%
CO2 in RPMI-1640 containing 10% fetal calf serum,
10 mm l-glutamine, 1% penicillin/streptomycin, 2.5%
HEPES buffer, and 1% amino acid solution.
Statistics
The evaluation of immunoreactivity was performed on
sections stained for CD1a and CD83. Because of the het-
erogeneous distribution of DC, the quantification was
performed by the hot-spot method. This method allows
quantification of cells in hot spots defined in this study
as areas containing the highest density of positive cells.
Accordingly, five hot spots per section were counted with
an eyepiece graticule at 400x magnification. Statistical
analyses were applied using GraphPad Prism (version
5.00 for Mac; GraphPad Software, San Diego, CA, USA).
Statistical comparisons were performed applying the
unpaired t-test or the Mann-Whitney test; p values
< 0.05 were considered as statistically significant.
Results
Immature DCs are present within the tumour tissue
To evaluate the total number of DCs in tumour tissues
of RCCs and the corresponding normal kidney tissues,
immunostaining for CD11c and Fascin was performed.
These markers have been shown to be widely expressed
by subsets of immature and mature myeloid DCs (19,
20). Unfortunately, both markers proved not to be speci-
fic for DCs in renal tissues. For instance, immunostain-
ing for CD11c (Figure 1a) revealed co-expression of this
antigen by numerous macrophages, which were predo-
minantly present within the tumour tissue and at the
tumour margin. Fascin demonstrated a strong cytoplas-
matic co-expression by tumour cells in >90% of the
cases investigated (Figure 1b). Fascin staining was found
to be heterogeneous within the tumour tissue. Thus, in
many cases the strongest cytoplasmatic expression for
Fascin was observed by tumour cells localized at the
infiltration border. Therefore, evaluation of immature
and mature DC subsets was performed by immunhisto-
chemistry for CD1a (Figure 1c) and CD83 (Figure 1d),
respectively.
Immature DCs were characterized by CD1a expression
(Figure 1c), and the LC subset of immature DCs
was further characterized by additional expression of
Langerin. In all samples, CD1a+ cells with dendritic
morphology were found randomly distributed through-
out the entire tumour beds. The number of CD1a+
immature DCs per high-power field within the tumour
tissue ranged from 1-24 cells, with mean and median
Table 2 PCR primers used for RT-PCR analysis of
chemokines
Gene Primer sequence Product size
MIP-3a 5’- CTGTACCAAGAGTTTGCTCC -3’ 193bp
5’- GCACAATATATTTCACCCAAG -3’
MIP-3b 5’-CCAGCCTCACATCACTCACACCTTGC-3’ 324 bp
5’-TGTGGTGAACACTACAGCAGGCACCC-3’
SLC 5’-AACCAAGCTTAGGCTGCTCCATCCCA-3’ 249 bp
5’-TATGGCCCTTTAGGGGTCTGTGACCG-3’
b-Actin 5’- CTACAATGAGCTGCGTGTGGC -3’ 270 bp
5’- CAGGTCCAGACGCAGGATGGC -3’
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numbers of 12 and 7, respectively (Figure 2a). Although
a majority of DCs were CD1a+/Langerin+ LCs (Figure
3a), CD1a+/Langerin- cells were also found. Langerin
co-expression was observed by 80%-90% of CD1a+ DCs.
The immaturity of CD1a+ DCs within the tumour tissue
was further demonstrated by the absence of maturity
markers, such as DC-LAMP, CD40, or RelB expression,
as assessed by serial analyses in confocal microscopy of
double fluorescence-stained sections. Normal kidney tis-
sues rarely displayed scattered CD1a+ cells. Three sec-
tions were negative, whereas 9 of the 24 sections
investigated showed <3 CD1a+ cells within the normal
kidney over the entire section. However, in four cases, a
weak-to-moderate chronic nephritis was present. In
these latter cases, focal aggregates of CD1a+ DCs were
observed due to the chronic inflammatory process.
Mature DCs accumulate in the peri-tumoural area
We next sought to determine if mature DCs were also
infiltrating RCC tumour tissues. Mature DCs were char-
acterized by expression of CD83 (Figure 1d). CD83+
mature myeloid DCs could be observed in all tumour
cases investigated. However, in all cases, a striking com-
partmentalization of CD83+ cells was observed. Thus,
only rare CD83+ DCs were observed within normal, kid-
ney tissues not affected by inflammation. As a rule, no
more than three CD83+ DCs could be observed within
the entire normal kidney area of the slides investigated.
Even in the tumour tissues, only rare CD83+ DCs were
observed. Thus, in 17 of the 24 investigated cases, no
CD83+ DCs were identified within the tumour tissue.
Most interestingly, numerous mature DCs were located
in the peri-tumoural normal kidney tissue in close vici-
nity to the typically observed pseudocapsule of RCCs
(Figure 1d). In the peri-tumoural area, the number of
CD83+ mature DCs per high-power field (400x) ranged
from 0-28 cells, with mean and median numbers of 6 and
7, respectively (Figure 2b). In addition, double staining
for DC-LAMP (Figure 3b), CD40 (Figure 3c), and nuclear
RelB (Figure 3d) confirmed the maturity of CD83+ DCs.
Figure 1 Immunohistochemistry for different DC markers.
CD11c is co-expressed by numerous macrophages within the
tumour tissue (A, 200x). Moderate-to-strong Fascin expression by
tumour cells of RCC (B, 100x). Numerous CD1a+ immature DCs can
be observed within the tumour stroma (C, 200x). CD83+ mature
dendritic cells are observed within T-cell aggregates, which are
located adjacent to the infiltration border of the tumour cells (D,
200x).
Figure 2 Quantification of CD1a (A) and CD83 (B) expressing dendritic cells (DCs) in RCC tissue, tumour infiltration border zone and
corresponding normal kidney. (A) Tumour tissue of RCC shows a statistically significant increased number of immature CD1a+ DCs (Mean:
14.44, SD: 19.59) compared to the tumour infiltration border zone (Mean: 4.621, SD: 5.577) and normal kidney tissue (Mean: 2.182, SD: 1.805). (B)
In contrast, a significant increased amount of mature CD83+ DCs is observed within the tumour infiltration border zone (Mean: 18.41, SD: 11.94)
compared to tumour tissue (Mean: 4.6608, SD: 4.364) and normal kidney (Mean: 4.784, SD: 3.282; Mann-Whitney test with Bonferroni correction; p
values < 0.05 were considered as statistically significant).
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T cells make clusters with mature DCs in the
peritumoural area
Because mature DCs can normally be found only in sec-
ondary lymphoid organs where they closely interact with
Ag-specific T cells, we next analyzed the T cell distribu-
tion and activation pattern in RCC samples. In 22 of the
24 evaluated samples, CD3+ T cells infiltrated peri-
tumoural areas, where they could be seen either scattered
throughout the area in close proximity to tumour cells or
clustered. Double-staining for CD3 and CD83 demon-
strated T cell clusters around mature DCs in the peri-
tumoural areas (Figure 3e). Typically, the DC/T-cell clus-
ters were located adjacent or around peri-tumoural lym-
phatic vessels. Occasionally, DC/T-cell clusters were
found within peri-tumoural lymph vessels. The majority of
infiltrating CD3+ T-cells (70%-75%) showed co-expression
for CD4. Approximately 5%-10% of T cells within the DC
T cell clusters at the tumour border showed signs of pro-
liferation, as shown by nuclear expression of the prolifera-
tion marker Ki67 (Mib-1; Figure 3f).
mRNA expression of lymphoid chemokines in renal cell
carcinoma tissue and tumour cell cultures
To explore the differential expression of the lymphoid
chemokines MIP-3a, MIP3-b, and SLC in RCC cell lines
and RCC tissue RT-PCR analyses were performed. RT-
PCR on total mRNA isolated from three established RCC
lines (A498, Caki-1, and Caki-2) showed abundant PCR
products for MIP-3a by all three cell lines investigated
(Figure 4). In contrast, no amplification products could
be obtained by RT-PCR for MIP-3b and SLC. mRNA iso-
lated from human lymph nodes served as a positive con-
trol, showing gene-specific amplification products for all
three genes.
Thus, additional studies were performed on the total
RNA isolated from the carcinoma tissue and corre-
sponding normal kidney tissue by quantitative real-time
RT-PCR (n = 10). For carcinoma-derived mRNA, a sta-
tistically significant increased expression of MIP-3a (p <
0.05) mRNA was observed in comparison to mRNA of
corresponding normal kidney tissue (Figure 5a).
Figure 3 Characteristics of DC subsets in RCC. By double immunfluorescence investigations the immature CD1a+ DCs (indocarbocyanine 3
(Cy3) - red fluorescence) in the tumour bed show co-expression for Langerin (indocarbocyanine 2 (Cy2) - green fluorescence; A, 400x). CD83+
DCs (Cy3 - red fluorescence) of the tumour border show co-expression for the maturation-associated antigens DC-LAMP (B), CD40 (C), and
nuclear-expressed RelB (D, all 400x, all Cy2 - green fluorescence). CD83+ DCs (Cy3 - red fluorescence) form clusters with CD3+ T-cells (E, 400x,
Cy2 - green fluorescence). T cells adjacent to the CD83+ mature DCs (Cy3 - red fluorescence) show an increased proliferation as indicated by
nuclear Mib-1 expression (F, 400x, Cy2 - green fluorescence).
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In contrast, no statistical significant difference was
detected for MIP-3b (p = 0.395; Figure 5b) and SLC (p
= 0.137; Figure 5c) between tumour mRNA and mRNA
isolated from corresponding normal kidney tissues.
Immunohistochemical analysis of MIP-3a, MIP-3b, and
SLC in RCC tissue and corresponding normal kidney
tissues
The expression of MIP-3a, MIP3-b, and SLC was then
evaluated by immunohistochemistry and double-immu-
nofluorescence on paraffin sections of the cases ana-
lyzed by RT-PCR. Immunostaining for MIP-3a was
observed within the cytoplasm of tumour cells in all
cases investigated (Figure 6a). Furthermore, expression
by tumour-associated macrophages was observed, as
determined by double-staining with the monocyte/
macrophage marker, CD68. A weak-to-moderate immu-
nostaining could also be observed by tubulus cells of
normal kidney tissues.
Immunohistochemistry for MIP-3b and SLC demon-
strated no staining of epithelial cells, including tumour
cells and normal kidney tubules. In addition, no staining
was observed by tumour-associated macrophages or
other inflammatory cells, such as CD3+ T-cells or
CD79a+ B-lymphocytes. In contrast, an increased num-
ber of MIP-3b-expressing cells were observed within
the T-cell clusters (Figure 6b). The cells expressing
MIP-3b proved to be mature myeloid dendritic cells
showing co-expression for CD83 (Figure 7a). Similarly,
an increased number of SLC-expressing dendritic-
shaped cells (Figure 6c) were observed within T cell
aggregates often in direct contact to CD11c and CD83-
positive DCs. The SLC-expressing cells within these T
cell clusters proved to be negative for DC markers
(CD1a, CD11c, and CD83), as well as antigens related
to T cells (CD3), B-cells (CD79a), or macrophages
(CD68, data not shown). Since the SLC-expressing cells
demonstrated expression of vimentin (data not shown),
they probably represent fibroblastic stromal cells which
have already been shown to represent the major source
of SLC-expressing cells within the lymph node paracor-
tex. Furthermore, we found an increased number of
lymphatic vessels in the peri-tumoural region, whereas
the tumours themselves were completely devoid of
lymph vessels as determined by immunostaining for the
lymphatic endothelial cell marker, D2-40. The lymphatic
vessels of the tumour border showed a strong expres-
sion for SLC (Figure 6c), as determined by co-expres-
sion for D2-40 (Figure 7b). The SLC-expressing
lymphatic vessels were typically observed within or adja-
cent to DC/T-cell clusters. In addition, occasional clus-
ters of T cells and DCs could be detected within these
SLC-positive lymphatic vessels.
Chemokine receptor expression by immature and mature
DCs in RCCs
CCR6-positive cells showing dendritic morphology were
randomly distributed throughout the tumour bed (Fig-
ure 6d) in all cases investigated. CD1a+ DCs within the
tumour area and normal kidney tissue demonstrated co-
expression for CCR6, whereas no expression for CCR7
could be observed as determined by immunohistochem-
istry and double-immunofluorescence studies. In addi-
tion, tumour cells and tubulus cells of normal kidney
demonstrated weak expression for CCR6. Occasionally,
expression of CCR6 was observed by tumour-associated
macrophages, CCR6-positive immature DCs were
observed within T cell clusters of the tumour border
zone (Figure 6e).
In contrast, lymphoid aggregates of the tumour border
demonstrated a strong expression for CCR7 (Figure 6f).
Within these clusters of CCR7-positive T cells numerous
Figure 4 RT-PCR analysis of MIP-3a, MIP-3b, and SLC mRNA
expression in renal carcinoma cell lines. RT-PCR showed
amplification products for MIP-3a in all three RCC cell lines (A498,
CAKI-1, and CAKI-2) investigated. In contrast, no amplification
products for MIP-3b and SLC were obtained. mRNA derived from
lymph node tissue served as positive control. Quality of cDNA was
checked by amplification for b-actin.
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Figure 5 Real-time RT-PCR analysis of MIP-3a, MIP-3b, and SLC mRNA expression. Total RNA was analyzed for MIP-3a (A), MIP-3b (B), and
SLC (C) mRNA expression by quantitative RT-PCR from tissue samples of RCC and corresponding normal kidney tissues of the same patient (n =
10). mRNA isolated from five normal lymph nodes served as positive controls showing abundant transcripts for MIP-3b and SLC, whereas only
weak expression for MIP-3a could be observed. RCC tissue demonstrated a significantly increased expression of MIP-3a mRNA compared to the
corresponding normal kidney (p = 0.0013). In contrast MIP-3b (p = 0,395) and SLC (p = 0,137) did not prove to be significantly different between
tumour tissue and controls.
Figure 6 Immunohistochemistry of chemokine and chemokine receptor expression in RCC. Tumour cells show moderate cytoplasmatic
expression for MIP-3a (A, 400x). Expression of MIP-3b is observed by DCs localized within lymphocyte aggregates at the tumour infiltration
border (B, 400x). SLC is expressed by lymphatic vessels (open arrows) and in addition by stromal cells (arrows) at the tumour infiltration border
(C, 400x). CCR6 positive cells with dendritic morphology are randomly distributed between the tumour cells (D, 400x). Few CCR6 positive DCs
can be observed within the lymphatic aggregates of the tumour border zone (arrows, E, 400x). Numerous CCR7+ cells are found within the
lympoid aggregates (F, 400x).
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CD83+ mature DCs showed co-expression for CCR7
(Figure 7c). CCR6 expression by mature DCs could not
be observed. As observed for CCR6 in some cases, weak
expression for CCR7 could be observed by tumour cells
and tubulus cells of normal kidney tissues as well.
Tumour-associated macrophages showed no expression
for CCR7.
Discussion
A RCC is considered to be one of the most immunore-
sponsive cancers in humans. During the last few decades,
promising new immunologic-based treatment strategies
for this tumour entity have been developed [18]. How-
ever, the tumour response is observed only in a subset of
patients. Thus, detailed knowledge of the mechanisms
underlying the immune response at the interface between
immune attack and immune suppression might help to
improve the promising immunotherapeutic approaches
in RCCs. More recently, emphasis has shifted to the use
of DC vaccines for active immunization of cancer
patients with in vitro-generated DCs, which have been
fused with tumour cells or loaded with tumour antigens
[19-21].
Different approaches of RCC vaccines have been
explored in the metastatic and adjuvant setting in several
studies [22,23]. Reviewing the current literature, about
20 non-randomised phase 1 or 2 immunotherapeutic trials
have been published for DC-vaccines in metastasized
RCCs [24-40]. As a summary, none of these patients
developed significant treatment-related toxicity or autoim-
munity-related side effects, while approximately 40% of
the patients demonstrated clinical tumour regression [18].
Nevertheless, the results of DC vaccination in these
non-randomised studies should be viewed with caution
because of the relative small number of patients within
each trial and the diversity of the vaccination strategies
used. Although most groups currently use monocyte-
derived DCs for clinical vaccine trials [41], the isolation
procedures of the monocytes, the differentiation proce-
dures towards DCs, and the loading and maturation
Figure 7 Two-colour immunofluorescence investigation of chemokine and chemokine receptor expression. MIP-3b (Cy2 - green
fluorescence) is expressed by CD83+ co-expressing DCs (Cy3 - red fluorescence; A, 600x). In contrast, SLC (Cy3 - red fluorescence) is co-
expressed by D2-40+ lymphatic endothelial cells (Cy2 - green fluorescence; B, 400x). Within the lymphatic infiltrates of the tumour border zone
CCR7 (Cy3 - red fluorescence) is co-expressed by CD83+ mature DCs (Cy2 - green fluorescence; C, 400x). Negative control (D, 400x).
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procedures are heterogeneous between the published clini-
cal studies [42]. Thus, the current data suggest that DC
vaccination in patients with metastatic RCCs appears to be
safe and results in a tumour-specific immune response
which can achieve tumour regression in a significant sub-
set of patients [18]. However, for efficient and reliable
immunotherapy of tumours, the optimal protocol for DC-
based vaccination remains to be clarified further. There-
fore, detailed knowledge concerning the immune response
in RCCs with special regard to the role of DCs in vivo is
required for development of an optimal vaccination strat-
egy. One very important issue in this context represents a
detailed knowledge concerning the type and distribution
of DC subsets, as well as the mechanisms underlying their
migration, maturation, and function in RCCs. Recent data
point to a significant role of DC subsets in Th1/Th2 polar-
ization and the induction of the tumour immune response
[14,43]. Thus, the determination of the origin and immune
competence of tumour-associated DCs will be of great
importance to our understanding of the development of
tumour immunity for RCCs [44]. Therefore, we investi-
gated the distribution and maturation of the different DC
subtypes in RCCs and corresponding normal kidney tis-
sues. The findings in the current study extend previous
investigations for other tumour entities [14,15,45,46]. The
results demonstrate a unique compartmentalization of
immature and mature DCs within kidneys affected by
RCCs.
All tumour samples displayed variable immature DC
infiltration. Tumour-infiltrating immature DCs were het-
erogeneous, and two populations were identified. One
population represented the CD1a+/Langerin+ Langer-
hans-cell type and the other type was CD1a+/Langerin-
non-Langerhans cell. Since dermal (interstitial) DCs were
found in vitro and in vivo to express CD1a, but not Lan-
gerin, we currently conclude that CD1a+/Langerin-
tumour-infiltrating DCs represent immature interstitial
DCs. The significance of this heterogeneity remains to be
established. Earlier studies revealed that interstitial DCs
generated in vitro from CD34+ precursors display more
potent phagocytic activity than LCs [1,3].
The observed numbers of immature CD1a+ DCs in
the tumour environment was much higher than in nor-
mal kidney tissues, suggesting increased homing and
infiltration of immature DCs by the tumour. This find-
ing was also been described by Troy et al. [47,48] nearly
a decade ago. This may be best explained by the high
levels of intratumoural MIP3-a, a chemokine, which is
known to specifically attract immature DCs. Our results
show an increased expression of MIP-3a by tumour
cells of RCCs by RT-PCR and immunohistochemistry.
The immunohistochemistry analysis with anti-MIP3-a is
unfortunately not precise enough to allow a correlation
between the amount of MIP3-a protein by the tumour
cells and the amount of infiltrating immature DCs.
However, our finding of an increased expression of
MIP-3a mRNA in RCC cell lines, as well as in RCC tis-
sue compared to mRNA derived from normal kidney,
underlines a role for an increased expression of MIP-3a
in homing or recruitment of immature DCs to RCC tis-
sues. The increased number of immature DCs could
also reflect a transient stage due to the high in-and-out
migration or the sequestering of immature DCs within
the tumour tissue. Another explanation might be
tumour-induced maturation arrest of tumour-infiltrating
DCs. Studies for different tumour entities have shown
that in cancer patients, DCs in the blood, tumour tis-
sues, and draining lymph nodes are often functionally
defective and possess poor T cell stimulatory capacity
[49]. One possible explanation for this observation
might be the expression of tumour-derived factors, such
as VEGF, TGF-b, and IL-10, which have been shown to
inhibit differentiation or functional maturation of DCs
[49-53]. Therefore, it has been suggested that immatur-
ity of DCs in the tumour tissue may mediate tumour
tolerance instead of immune activation caused by induc-
tion of T-cell anergy or favouring the development of
regulatory T cells [54,55].
However, in contrast to the observed immaturity of
intratumoural DCs, the more important finding might
be the presence of numerous mature DCs accumulating
specifically within the peri-tumoural areas. This finding
suggests that additional factors might be involved in
mature DC distribution. Because mature DCs are typi-
cally observed in lymphoid organs, where they closely
interact with T cells, it is tempting to consider that their
presence within the tumour tissue might reflect an
ongoing tumour-specific immune response. Thus, the
mature DCs could derive from any of the immature DC
subset discussed above within the tumour tissues. The
peri-tumoural localization of mature DCs observed in
our study corresponds to observations in other tumour
types, and RCC as well [15,47]. The preferential localiza-
tion of mature DCs in lymphocyte-rich peri-tumoural
areas of RCCs could be due to the resemblance of these
areas to secondary lymphoid organs where mature DCs
are normally found.
What instigates the mechanisms underlying the accu-
mulation of mature DCs with a prominent T cell
response in RCCs. Our results support the concept that
specific homing of CCR7+ leucocytes to the tumour
border may contribute to the anti-tumour response in
RCCs, which at least partly resembles de novo develop-
ment of a tertiary lymphoid tissue at the invasive margin
of the tumours. Our results show a significant increased
expression of lymphoid chemokines (SLC and MIP-3b)
at the tumour border in contrast to tumour and normal
kidney tissues. These results imply that the increased
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expression of SLC and MIP-3b may lead to a chemokine
microenvironment normally observed in secondary lym-
phatic tissues. Expression of these chemokines favours
homing and interaction of CCR7-expressing cells, such
as mature myeloid DCs and naïve or memory T cells,
facilitating their interaction for an optimal anti-tumour
immune response. Thus, in analogy to secondary lym-
phoid organs, such as lymph nodes, chemokine-depen-
dant co-localization of T-cells and antigen-presentation
occurs at the tumour border, leading to the local gen-
eration of anti-tumour-specific T cells.
Interestingly, various studies have shown that the pre-
sence of a dense DC infiltration has been associated with
prolonged survival and reduced incidence of metastases in
patients with various human cancers, such as colorectal,
gastric, esophageal, oral, and lung carcinoma [56-59]. In
breast cancer, the number of CD83+ mature DCs, but not
the number of CD1a+ or S100+ DCs, has been shown to
be of prognostic relevance [60]. In light of their impor-
tance in anti-tumour immunity, surprisingly few studies
have been aimed at the presence of DCs and its potential
clinical correlates in RCCs. For interferon pre-treated
RCCs a trend toward a better outcome and better prog-
nosis has been found in patients with a higher number of
S100+ DCs within the tumour tissue [61,62]. Although
S100 protein has long been used to indicate DCs, its sig-
nificance is still under confusion. In our experiments, we
found S100 protein to be co-expressed by numerous
CD68+ macrophages. Thus, S100 immunohistochemistry
was not suitable for evaluation of DC numbers in RCCs
(data not shown). In a more recent study, Kobayashi et al.
[63] investigated whether or not the local immune envir-
onment might be associated with the tumour response fol-
lowing treatment with interferon-a and interleukin-2 in
RCCs. Their results demonstrated a higher number of
mature CD83+ DCs in tumour tissue of responders fol-
lowing cytokine treatment. In addition, the responders
survived longer than non-responders. In contrast, other
tumour-associated immune cells, such as CD8+ T-cells or
tumour-associated macrophages, were not associated with
treatment response or survival outcome. Thus, the pre-
sence of high number of CD83+ mature DCs might repre-
sent a predictive factor for the clinical outcome in patients
with RCCs [63].
Conclusions
These and our observations suggest that the presence of
an “immunologic functional unit” in RCCs consisting of
antigen-presenting DCs and activated T cells at the
tumour border might represent prognostic significance.
In this scenario the combination of a low number or
absence of DCs with a low density of activated T cells
would predict a worse outcome, while a high density of
mature DCs and activated T cells predicts a favourable
disease outcome. This would also suggest that the pre-
sence of mature antigen-presenting DCs at the primary
site together with that of activated T cells, represents a
functional immune response against RCC progression.
Thus, our observations open new insight regarding DC
involvement and function concerning the anti-tumour
response in RCCs. However, the limited number of RCC
tumour samples analyzed in this study and the short fol-
low-up times does not allow us to establish a prognostic
significance of the infiltration of tumour by immature or
mature DCs. Such determination will require the analy-
sis of a large number of samples in prospective or retro-
spective studies. Therefore, further analysis of the APC
system will provide clues to the understanding of
tumour immunity as well as improvement of the effi-
ciency of vaccine strategies in RCCs and other immuno-
genic tumour entities.
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